research Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
Search
for
Sort by
Research
810-840 / 1000+ results 
research Efficacy and safety of baricitinib in patients with refractory alopecia areata
Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
research Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha
Topical IKKα inhibitors may help prevent CCS tumours.
research The Current State of Patient Adherence to Lab Monitoring Guidelines for Janus Kinase Inhibitors in Patients with Alopecia Areata.
Patients with alopecia areata using Janus kinase inhibitors are not following lab monitoring guidelines.
research The role of janus kinases in the treatment of autoimmune skin diseases
Janus kinase inhibitors show promise in treating autoimmune skin diseases.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research Visual Improvement in a Child With Periorbital Plexiform Neurofibroma Treated With Selumetinib: Case Report and Literature Review
Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
research 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
research Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
research Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24‐Week Outcomes From a Prospective Real‐World Cohort
Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
research Efficacy of baricitinib in treatment of coexisting alopecia areata and lichen planopilaris
Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.
research Dual aspects of B cells in tumor immunity; B cells are capable of positive and negative regulation for tumor immunity against B16 melanoma
B cells can both help and hinder the body's defense against melanoma.
research 93 Approach to Managing Recalcitrant Alopecia Areata With Combination Therapy: A Series of Five Cases in Black Pediatric Patients
Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
research Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
Deucravacitinib helped a man regrow hair and improve psoriasis.
research PRIDE syndrome associated with panitumumab treatment – case report and literature review
A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
research 320 An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata
Abatacept may help some people with alopecia areata regrow hair.
research Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
research Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research KRT17: A Key Driver of Cancer Therapy Resistance and Emerging Therapeutic Target
Targeting Keratin 17 may help overcome cancer therapy resistance.
research Supplementary Material for: TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
research IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
research Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
research PROTACs: A novel strategy for cancer drug discovery and development
PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/research/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.